Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesEW +0.65%97 Debt-to-EBITDA is 0.32 as of Mar. 2026, which is 37% below its 10-year median of 0.51. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.72 (Fairly Valued). The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 73.56% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Edwards Lifesciences's Debt-to-EBITDA or its related term are showing as below:
EW'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.37 Med: 0.51 Max: 0.99
Current: 0.45
During the past 13 years, the highest Debt-to-EBITDA Ratio of Edwards Lifesciences was 0.99. The lowest was 0.37. And the median was 0.51.
EW's Debt-to-EBITDA is ranked better than 73.56% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs EW: 0.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Edwards Lifesciences Debt-to-EBITDA Related Terms
Edwards Lifesciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Edwards Lifesciences (EW) has a Debt-to-EBITDA of 0.32 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Edwards Lifesciences. This is 37% below median its historical median of 0.51. Over the past decade, Edwards Lifesciences' Debt-to-EBITDA has ranged from 0.37 to 0.99. According to the industry distribution chart, Edwards Lifesciences ranks #124 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 26.4%.
Is Edwards Lifesciences' Debt-to-EBITDA too high?
Edwards Lifesciences' current Debt-to-EBITDA of 0.32 is 37% below median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.99. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Edwards Lifesciences' value of 0.32 is 80% below this industry median. Based on the distribution chart, Edwards Lifesciences ranks #124 out of 469 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Debt-to-EBITDA compare to BSX and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #124 out of 469 companies for Debt-to-EBITDA. This puts Edwards Lifesciences in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. Edwards Lifesciences' value of 0.32 is 80% below this benchmark. Historically, Edwards Lifesciences' own Debt-to-EBITDA has ranged from 0.37 to 0.99 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 1.60, Edwards Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Debt-to-EBITDA of 0.32 is 80% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Edwards Lifesciences. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Debt-to-EBITDA is 0.32, which is 37% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.72, compared to a current price of $87.84 — trading 6.3% below its estimated fair value. The current Debt-to-EBITDA is 0.32, which is 37% below median its 10-year median of 0.51 and 80% below the Medical Devices & Instruments industry median of 1.60. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Debt-to-EBITDA is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $87.84 is trading 6.3% below its estimated GF Value™ of $93.72.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for EW:
Debt-to-EBITDA: 0.32 (37% below median its 10-year median of 0.51)
GF Value™: $93.72 vs. price of $87.84 (6.3% below fair value)
Industry Position: 80% below the Medical Devices & Instruments median (#124 of 469)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
